Analysts’ updated eps estimates for Friday, March 7th:
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its equal weight rating reaffirmed by analysts at Morgan Stanley. The firm currently has a $20.00 target price on the stock.
Adicet Bio (NASDAQ:ACET) had its neutral rating reiterated by analysts at HC Wainwright.
Alector (NASDAQ:ALEC) had its underweight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $1.50 target price on the stock, down from their previous target price of $3.00.
ALX Oncology (NASDAQ:ALXO) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $5.00 target price on the stock.
American Public Education (NASDAQ:APEI) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $24.00 target price on the stock.
Arcturus Therapeutics (NASDAQ:ARCT) had its overweight rating reissued by analysts at Cantor Fitzgerald.
Ardelyx (NASDAQ:ARDX) had its buy rating reaffirmed by analysts at LADENBURG THALM/SH SH. LADENBURG THALM/SH SH currently has a $11.00 target price on the stock.
Asure Software (NASDAQ:ASUR) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $20.00 price target on the stock.
Asure Software (NASDAQ:ASUR) had its outperform rating reissued by analysts at Barrington Research. The firm currently has a $17.00 price target on the stock.
Asure Software (NASDAQ:ASUR) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $13.00 target price on the stock.
ArriVent BioPharma (NASDAQ:AVBP) had its buy rating reissued by analysts at HC Wainwright. They currently have a $39.00 price target on the stock.
Broadcom (NASDAQ:AVGO) had its buy rating reaffirmed by analysts at Rosenblatt Securities. The firm currently has a $250.00 price target on the stock.
Broadcom (NASDAQ:AVGO) had its buy rating reissued by analysts at Benchmark Co.. The firm currently has a $255.00 target price on the stock.
Broadcom (NASDAQ:AVGO) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $300.00 price target on the stock.
Broadcom (NASDAQ:AVGO) had its outperform rating reaffirmed by analysts at William Blair.
Atea Pharmaceuticals (NASDAQ:AVIR) had its outperform rating reissued by analysts at William Blair.
AstraZeneca (LON:AZN) had its buy rating reiterated by analysts at Shore Capital.
Black Diamond Therapeutics (NASDAQ:BDTX) had its outperform rating reissued by analysts at Wedbush. They currently have a $11.00 price target on the stock, down from their previous price target of $16.00.
BlackSky Technology (NYSE:BKSY) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $20.00 target price on the stock.
BlackSky Technology (NYSE:BKSY) had its buy rating reiterated by analysts at Benchmark Co.. Benchmark Co. currently has a $17.00 target price on the stock.
Cidara Therapeutics (NASDAQ:CDTX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $35.00 price target on the stock.
Confluent (NASDAQ:CFLT) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $40.00 price target on the stock.
Confluent (NASDAQ:CFLT) had its outperform rating reaffirmed by analysts at William Blair.
Cullinan Therapeutics (NASDAQ:CGEM) had its overweight rating reissued by analysts at Morgan Stanley. The firm currently has a $35.00 target price on the stock, down from their previous target price of $38.00.
CG Oncology (NASDAQ:CGON) had its overweight rating reissued by analysts at Morgan Stanley. The firm currently has a $55.00 price target on the stock.
Centessa Pharmaceuticals (NASDAQ:CNTA) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $27.00 target price on the stock.
Cooper Companies (NASDAQ:COO) had its overweight rating reissued by analysts at Piper Sandler. Piper Sandler currently has a $115.00 price target on the stock, down from their previous price target of $120.00.
Cooper Companies (NASDAQ:COO) had its hold rating reiterated by analysts at Needham & Company LLC.
CytomX Therapeutics (NASDAQ:CTMX) had its neutral rating reaffirmed by analysts at HC Wainwright.
CytomX Therapeutics (NASDAQ:CTMX) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $5.00 price target on the stock.
Contineum Therapeutics (NASDAQ:CTNM) had its overweight rating reaffirmed by analysts at Morgan Stanley. The firm currently has a $25.00 price target on the stock.
Carvana (NYSE:CVNA) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $340.00 target price on the stock.
HF Sinclair (NYSE:DINO) had its overweight rating reiterated by analysts at Piper Sandler. The firm currently has a $49.00 price target on the stock.
DICK’S Sporting Goods (NYSE:DKS) had its outperform rating reissued by analysts at Telsey Advisory Group. The firm currently has a $260.00 target price on the stock.
Domo (NASDAQ:DOMO) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. They currently have a $11.00 target price on the stock.
Elevation Oncology (NASDAQ:ELEV) had its outperform rating reissued by analysts at William Blair. William Blair currently has a $5.00 price target on the stock.
Elevation Oncology (NASDAQ:ELEV) had its overweight rating reissued by analysts at Stephens. Stephens currently has a $5.00 price target on the stock.
Elutia (NASDAQ:ELUT) had its overweight rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $8.00 price target on the stock.
Erasca (NASDAQ:ERAS) had its overweight rating reiterated by analysts at Morgan Stanley. They currently have a $4.00 price target on the stock.
Foghorn Therapeutics (NASDAQ:FHTX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $13.00 target price on the stock.
Formula One Group (NASDAQ:FWONK) had its buy rating reaffirmed by analysts at Rosenblatt Securities. They currently have a $102.00 price target on the stock.
GAP (NYSE:GAP) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. They currently have a $26.00 price target on the stock.
Granite Ridge Resources (NYSE:GRNT) had its overweight rating reiterated by analysts at Stephens. They currently have a $8.00 price target on the stock.
Guidewire Software (NYSE:GWRE) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Hikma Pharmaceuticals (LON:HIK) had its overweight rating reiterated by analysts at JPMorgan Chase & Co..
Humacyte (NASDAQ:HUMA) had its buy rating reiterated by analysts at D. Boral Capital. They currently have a $25.00 price target on the stock.
Hut 8 (NASDAQ:HUT) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $30.00 price target on the stock.
InflaRx (NASDAQ:IFRX) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $8.00 target price on the stock.
Immunocore (NASDAQ:IMCR) had its equal weight rating reiterated by analysts at Morgan Stanley. Morgan Stanley currently has a $35.00 price target on the stock.
Disc Medicine (NASDAQ:IRON) had its overweight rating reaffirmed by analysts at Morgan Stanley. The firm currently has a $85.00 target price on the stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its overweight rating reissued by analysts at Morgan Stanley. The firm currently has a $183.00 price target on the stock, up from their previous price target of $175.00.
Just Group (LON:JUST) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. They currently have a GBX 200 ($2.58) target price on the stock.
Lucid Group (NASDAQ:LCID) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $5.00 target price on the stock.
Lennox International (NYSE:LII) had its overweight rating reaffirmed by analysts at Stephens. Stephens currently has a $750.00 target price on the stock.
Mitchells & Butlers (LON:MAB) had its buy rating reiterated by analysts at Shore Capital.
MoneyLion (NYSE:ML) had its hold rating reissued by analysts at Needham & Company LLC.
MeridianLink (NYSE:MLNK) had its outperform rating reissued by analysts at William Blair.
Mind Medicine (MindMed) (NASDAQ:MNMD) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $55.00 price target on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its overweight rating reiterated by analysts at Morgan Stanley. The firm currently has a $150.00 target price on the stock, down from their previous target price of $185.00.
National CineMedia (NASDAQ:NCMI) had its neutral rating reaffirmed by analysts at William Blair. The firm currently has a $7.50 price target on the stock.
National CineMedia (NASDAQ:NCMI) had its buy rating reissued by analysts at Benchmark Co.. The firm currently has a $8.00 price target on the stock.
ServiceNow (NYSE:NOW) had its outperform rating reiterated by analysts at William Blair.
NextCure (NASDAQ:NXTC) had its buy rating reissued by analysts at HC Wainwright. They currently have a $3.00 price target on the stock, down from their previous price target of $4.00.
Oruka Therapeutics (NASDAQ:ORKA) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $40.00 target price on the stock.
Potbelly (NASDAQ:PBPB) had its buy rating reissued by analysts at Benchmark Co.. The firm currently has a $16.00 price target on the stock.
Potbelly (NASDAQ:PBPB) had its market perform rating reissued by analysts at William Blair.
PDS Biotechnology (NASDAQ:PDSB) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $21.00 target price on the stock.
Phathom Pharmaceuticals (NASDAQ:PHAT) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $28.00 target price on the stock.
Priority Technology (NASDAQ:PRTH) had its outperform rating reissued by analysts at Keefe, Bruyette & Woods. They currently have a $12.00 price target on the stock, down from their previous price target of $14.00.
PTC Therapeutics (NASDAQ:PTCT) had its overweight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $70.00 target price on the stock, up from their previous target price of $67.00.
Relay Therapeutics (NASDAQ:RLAY) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $16.00 price target on the stock.
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its overweight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $72.00 price target on the stock.
Softcat (LON:SCT) had its buy rating reissued by analysts at Shore Capital.
Urban Logistics REIT (LON:SHED) had its buy rating reiterated by analysts at Shore Capital.
Silence Therapeutics (NASDAQ:SLN) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $75.00 target price on the stock.
SouthState (NASDAQ:SSB) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $130.00 price target on the stock.
Stevanato Group (NYSE:STVN) had its outperform rating reiterated by analysts at William Blair.
Trevi Therapeutics (NASDAQ:TRVI) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $21.00 price target on the stock.
Trade Desk (NASDAQ:TTD) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $145.00 target price on the stock.
VF (NYSE:VFC) had its market perform rating reiterated by analysts at Telsey Advisory Group. They currently have a $27.00 price target on the stock.
VF (NYSE:VFC) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $28.00 target price on the stock.
Warner Bros. Discovery (NASDAQ:WBD) had its neutral rating reaffirmed by analysts at Rosenblatt Securities. The firm currently has a $13.00 price target on the stock.
Wendy’s (NASDAQ:WEN) had its neutral rating reiterated by analysts at Wedbush. The firm currently has a $16.00 target price on the stock.
Wendy’s (NASDAQ:WEN) had its hold rating reiterated by analysts at TD Securities. The firm currently has a $16.00 target price on the stock.
Xeris Biopharma (NASDAQ:XERS) had its neutral rating reaffirmed by analysts at Piper Sandler. They currently have a $4.00 price target on the stock, up from their previous price target of $3.00.
Xeris Biopharma (NASDAQ:XERS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $8.00 target price on the stock, up from their previous target price of $6.60.
ZOOZ Power (NASDAQ:ZOOZ) had its speculative buy rating reiterated by analysts at Benchmark Co.. They currently have a $5.00 price target on the stock.
Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
